Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Tromsø Study
Summary
This summary is machine-generated.Circulating N-terminal pro-atrial natriuretic peptide (N-ANP) levels predict left ventricular hypertrophy in the general population. Elevated N-ANP is an independent predictor of left ventricular hypertrophy, even after adjusting for risk factors.
Area Of Science
- Cardiology
- Biomarkers
- Clinical Research
Background
- Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular events.
- Identifying reliable predictors of LVH in the general population is crucial for early intervention.
Purpose Of The Study
- To investigate whether circulating N-terminal pro-atrial natriuretic peptide (N-ANP) levels predict left ventricular hypertrophy (LVH).
- To assess N-ANP as a predictor in the general population, adjusting for established risk factors.
Main Methods
- A population-based sample of 389 subjects (aged 25-85 years) was analyzed.
- Left ventricular mass and ejection fraction were determined using echocardiography.
- LVH was defined based on height-adjusted left ventricular mass criteria for men and women.
Main Results
- Subjects with LVH exhibited significantly higher N-ANP levels compared to controls (1075 vs 763 pmol/L).
- A positive trend was observed between increasing N-ANP levels and LVH prevalence (1.8% to 64.3%).
- N-ANP independently predicted LVH (OR 1.79 per 500 pmol/L increase) after adjusting for age, gender, BMI, hypertension, and cardiac history.
Conclusions
- Circulating N-ANP is an independent predictor of left ventricular hypertrophy in the general population.
- N-ANP measurement is not optimal for differentiating isolated LVH from LVH with dysfunction.
View abstract on PubMed